NEO

Neogenomics Inc

17.98

Oct 30 • 9:38 AM ET +0.05 (0.27%)

Healthcare Diagnostics & Research USA Mid NASD

Oct 29, 1:12 AMNeoGenomics beats Q3 2026 estimates with EPS $0.07, revenue $209.3M, raises 2026 outlook as NGS growth and margins beat internal expectations

Peers: PSNL LH ADPT DGX VCYT GH FLGT TEM NTRA CAI

| Held by: IJR FBT VTI IWM VB VBK VXF XSMO SPSM IWN

Scroll to Statements

Index	RUT
Market Cap	2.33B
Enterprise Value	2.64B
Income	-32.30M
Sales	787.75M
Book/sh	6.20
Cash/sh	1.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2500
IPO	Nov 10, 1999

P/E	-
Forward P/E	56.99
PEG	1.09
P/S	2.95
P/B	2.90
P/C	16.70
P/FCF	-
EV/EBITDA	140.22
EV/Sales	3.35
Quick Ratio	3.31
Current Ratio	3.53
Debt/Eq	0.56
LT Debt/Eq	0.55
Option/Short	Yes / Yes

EPS (ttm)	-0.25
EPS next Y	0.32
EPS next Q	0.07
EPS this Y	68.18%
EPS next Y	56.31%
EPS next 5Y	52.34%
EPS past 3/5Y	10.12% -
Sales past 3/5Y	12.58% 10.35%
EPS Y/Y TTM	71.76%
Sales Y/Y TTM	11.08%
EPS Q/Q	72.22%
Sales Q/Q	11.43%
Earnings	Oct 28 AMC
EPS/Sales Surpr.	26.13% 1.23%

Insider Own	1.93%
Insider Trans	-1.22%
Inst Own	113.82%
Inst Trans	10.47%
ROA	-2.35%
ROE	-3.94%
ROIC	-2.60%
Gross Margin	42.65%
Oper. Margin	-5.89%
Profit Margin	-4.10%
SMA20	6.22%
SMA50	1.60%
SMA200	40.62%
Trades

Shs Outstand	129.10M
Shs Float	126.00M
Short Float	11.28%
Short Ratio	6.75
Short Interest	14.22M
52W High	20.15 -10.77%
52W Low	7.07 154.48%
Volatility	4.75% 5.61%
ATR (14)	0.85
RSI (14)	56.38
Beta	1.87
Rel Volume	0.35
Avg Volume	2.11M
Volume	53,468

Perf Week	8.37%
Perf Month	1.12%
Perf Quarter	13.50%
Perf Half Y	90.45%
Perf YTD	52.88%
Perf Year	85.54%
Perf 3Y	32.10%
Perf 5Y	-60.92%
Perf 10Y	123.34%
Recom	1.50
Target Price	23.40
Prev Close	17.93
Price	17.98
Change %	0.27%

Consensus

Buy

Avg. Price Target

$23.40

Implied Upside

+30.2%

Analysts12incl. previous ratings

Rating Distribution7 Buy · 5 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 06, 2026	Upgrade	BBTIG Research	Neutral → Buy	$28	+55.7%
Apr 29, 2026	Upgrade	LLeerink Partners	Market Perform → Outperform	$25	+39.1%
Jul 30, 2025	Downgrade	BBTIG Research	Buy → Neutral
Jul 29, 2025	Downgrade	WWilliam Blair	Outperform → Mkt Perform
May 15, 2025	Initiated	GGuggenheim	Neutral
Apr 30, 2025	Downgrade	LLeerink Partners	Outperform → Market Perform	$9	-49.9%
Jan 13, 2025	Downgrade	TThe Benchmark Company	Buy → Hold
Dec 10, 2024	Initiated	JJefferies	Buy	$22	+22.4%
May 01, 2024	Resumed	CCraig Hallum	Buy	$26	+44.6%
Dec 29, 2023	Reiterated	BBTIG Research	Buy	$25 → $21	+16.8%
Aug 21, 2023	Upgrade	SStephens	Equal-Weight → Overweight	$18	+0.1%
May 16, 2023	Downgrade	RRaymond James	Outperform → Mkt Perform
May 09, 2023	Upgrade	BBTIG Research	Neutral → Buy	$25	+39.1%
Feb 24, 2023	Upgrade	TThe Benchmark Company	Hold → Buy	$20	+11.2%
Feb 01, 2023	Upgrade	NNeedham	Hold → Buy	$15	-16.6%
Aug 26, 2022	Downgrade	TThe Benchmark Company	Buy → Hold
Aug 22, 2022	Downgrade	NNeedham	Buy → Hold
Jun 03, 2022	Initiated	PPiper Sandler	Overweight	$13	-27.7%
Mar 29, 2022	Downgrade	SStephens	Overweight → Equal-Weight	$34 → $16	-11.0%
Mar 29, 2022	Downgrade	BBofA Securities	Buy → Neutral	$25 → $18	+0.1%

Oct-28-26 06:27PM	NeoGenomics Tops Consensus But Misses The Whisper As NGS Acceleration And A Third Guidance Raise Collide With Thin Cash Conversion (Earnings Whispers)
04:59PM	NeoGenomics: Q3 Earnings Snapshot (Associated Press)
04:05PM	NeoGenomics Reports Third Quarter 2026 Results (Business Wire)
Oct-20-26 05:26PM	NeoGenomics Faces A Tough Third-Quarter Comp After Three Straight Guidance Raises (Earnings Whispers)
Oct-15-26 07:05AM	NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology (Business Wire)
07:05AM	Loading…
Oct-14-26 07:05AM	NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026 (Business Wire)
Oct-06-26 01:09PM	NeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue Beat (TIKR) -13.72%
Oct-05-26 05:34PM	NeoGenomics stock falls on CEO transition announcement (Investing.com)
04:05PM	NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan (Business Wire)
Sep-01-26 07:05AM	NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference (Business Wire)
Aug-26-26 11:13PM	Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? (Stocktwits) +7.31%
04:17PM	NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring (Business Wire)
Jul-29-26 01:02AM	NeoGenomics Inc (NEO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Raised ... (GuruFocus.com) +13.96%
Jul-28-26 04:25PM	NeoGenomics: Q2 Earnings Snapshot (Associated Press)
04:05PM	NeoGenomics Reports Second Quarter 2026 Results (Business Wire)
05:23PM	Loading…
Jul-20-26 05:23PM	NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS (Business Wire)
Jul-09-26 07:05AM	NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer (Business Wire)
Jul-07-26 07:05AM	NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026 (Business Wire)
Jul-02-26 06:41PM	CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology (Exec Edge)
Jun-25-26 07:05AM	NeoGenomics Appoints Carolyn Starrett to its Board of Directors (Business Wire) +6.43%
Jun-17-26 06:00AM	NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes (Business Wire)
Jun-15-26 05:24PM	NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes (Business Wire) -5.41%
May-15-26 09:05AM	NeoGenomics to Participate in Upcoming Investor Conferences (Business Wire)
Apr-29-26 07:27AM	NeoGenomics Shares Jump on Earnings and Analyst Upgrades (InvestorsHub)
03:09AM	NeoGenomics Inc (NEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Apr-28-26 04:58PM	NeoGenomics: Q1 Earnings Snapshot (Associated Press)
04:05PM	NeoGenomics Reports First Quarter 2026 Results (Business Wire)
Apr-23-26 12:33PM	SkylineDx Presents Gene Expression Profiling for Skin Cancer Metastases (Exec Edge)
07:05AM	NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration (Business Wire)
Apr-13-26 07:05AM	NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026 (Business Wire)
07:05AM	Loading…
Apr-07-26 07:05AM	NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026 (Business Wire)
Mar-16-26 07:05AM	NeoGenomics PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling (Business Wire)
Feb-25-26 11:08PM	3 Reasons to Avoid NEO and 1 Stock to Buy Instead (StockStory)
07:05AM	NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types (Business Wire)
Feb-24-26 12:33AM	5 Insightful Analyst Questions From NeoGenomics's Q4 Earnings Call (StockStory)
Feb-20-26 09:35AM	After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO) (Zacks)
Feb-18-26 03:55PM	Why NeoGenomics (NEO) Shares Are Falling Today (StockStory) -10.31%
07:05AM	NeoGenomics to Participate in Upcoming Investor Conferences (Business Wire)
12:32AM	NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook (StockStory)
Feb-17-26 04:02PM	NeoGenomics Inc (NEO) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
10:42AM	NeoGenomics Q4 Earnings Call Highlights (MarketBeat)
08:15AM	NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:35AM	NeoGenomics's (NASDAQ:NEO) Q4 CY2025 Sales Beat Estimates (StockStory)
07:26AM	NeoGenomics: Q4 Earnings Snapshot (Associated Press Finance)
07:05AM	NeoGenomics Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
Feb-16-26 08:59AM	NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro (Zacks)
Feb-15-26 10:03PM	NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For (StockStory)
Feb-12-26 07:05AM	NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection (Business Wire)
Jan-27-26 07:05AM	NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 (Business Wire)
Jan-12-26 07:05AM	NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue (Business Wire) -5.09%
Jan-05-26 07:05AM	NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-30-25 07:05AM	NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. Jack Kenny to its Board of Directors (Business Wire)
Dec-16-25 11:33PM	3 Stocks Under $50 We Steer Clear Of (StockStory)
Dec-15-25 07:05AM	NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation (Business Wire)
Dec-10-25 07:05AM	NeoGenomics to Present New ctDNA Research at SABCS 2025 (Business Wire)
Dec-08-25 08:05AM	NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 (Business Wire)
Dec-05-25 11:19AM	Testing & Diagnostics Services Stocks Q3 Recap: Benchmarking NeoGenomics (NASDAQ:NEO) (StockStory)
Nov-21-25 06:36PM	NeoGenomics, Fortrea, and Acadia Healthcare Shares Skyrocket, What You Need To Know (StockStory) +8.30%
Nov-06-25 07:05AM	NeoGenomics to Participate in Upcoming Investor Conferences (Business Wire)
Nov-04-25 12:38AM	The Top 5 Analyst Questions From NeoGenomics's Q3 Earnings Call (StockStory)
Nov-03-25 11:01PM	NeoGenomics (NEO): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Oct-30-25 12:51PM	NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors (Business Wire) -5.74%
Oct-29-25 01:33AM	NEO Q3 Deep Dive: Clinical Volume Gains and New Product Launches Shape Outlook (StockStory)
Oct-28-25 12:11PM	Why NeoGenomics (NEO) Stock Is Trading Up Today (StockStory)
08:15AM	NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
07:49AM	NeoGenomics's (NASDAQ:NEO) Q3 Sales Top Estimates, Stock Soars (StockStory)
07:15AM	NeoGenomics: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	NeoGenomics Reports Third Quarter 2025 Results (Business Wire)
Oct-26-25 11:15PM	NeoGenomics (NEO) Reports Earnings Tomorrow: What To Expect (StockStory)
Oct-24-25 12:39AM	3 Healthcare Stocks Walking a Fine Line (StockStory)
Oct-23-25 07:10AM	Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains? (Zacks)
Oct-16-25 03:54AM	NeoGenomics (NEO) Moves 6.3% Higher: Will This Strength Last? (Zacks)
Oct-14-25 07:05AM	NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025 (Business Wire)
Oct-07-25 07:05AM	NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025 (Business Wire)
Sep-24-25 09:10AM	Here's Alger Weatherbie Specialized Growth Fund's Comment on NeoGenomics (NEO) (Insider Monkey)
Sep-10-25 04:35PM	Why NeoGenomics (NEO) Shares Are Falling Today (StockStory) +11.50%
Sep-04-25 09:36AM	Brown Advisory Small-Cap Growth Strategy Sold Neogenomics (NEO) Following the News of CEO Departure (Insider Monkey)
Sep-02-25 09:30AM	Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands (PR Newswire)
Aug-29-25 05:05PM	Health Care Roundup: Market Talk (The Wall Street Journal) +21.78%
01:46PM	Why Is NeoGenomics (NEO) Stock Soaring Today (StockStory)
01:04PM	NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims (Benzinga)
Aug-26-25 08:42AM	Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership (Zacks)
Aug-20-25 11:36PM	Testing & Diagnostics Services Stocks Q2 Teardown: NeoGenomics (NASDAQ:NEO) Vs The Rest (StockStory)
Aug-13-25 05:51PM	NeoGenomics, Progyny, Repligen, Revvity, and Waters Corporation Shares Are Soaring, What You Need To Know (StockStory)
Aug-12-25 12:56AM	NEO Q2 Deep Dive: Guidance Reset Amid Pharma Weakness, Delayed Product Launches (StockStory)
12:39AM	NeoGenomics's Q2 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Aug-07-25 03:36PM	Why NeoGenomics (NEO) Stock Is Trading Up Today (StockStory)
Jul-30-25 09:55AM	Down 29.2% in 4 Weeks, Here's Why NeoGenomics (NEO) Looks Ripe for a Turnaround (Zacks)
09:40AM	Peloton upgraded, Booking downgraded: Wall Street's top analyst calls (The Fly)
07:05AM	NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy (Business Wire)
05:07AM	Fort Myers-based NeoGenomics sees stock plunge after reporting mixed results for Q2 (The News-Press)
Jul-29-25 02:26PM	Why NeoGenomics (NEO) Shares Are Falling Today (StockStory) -18.73%
08:15AM	NeoGenomics (NEO) Meets Q2 Earnings Estimates (Zacks)
07:57AM	NeoGenomics (NASDAQ:NEO) Misses Q2 Sales Targets, Stock Drops 15.8% (StockStory)
07:14AM	NeoGenomics: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	NeoGenomics Reports Second Quarter 2025 Results (Business Wire)
Jul-27-25 11:08PM	NeoGenomics (NEO) Reports Q2: Everything You Need To Know Ahead Of Earnings (StockStory)
Jul-24-25 10:00AM	Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-14-25 11:31PM	Q1 Earnings Highlights: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Testing & Diagnostics Services Stocks (StockStory)
Jul-11-25 03:30PM	NeoGenomics, RadNet, Pediatrix Medical Group, Penumbra, and Neogen Shares Plummet, What You Need To Know (StockStory)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stone Warren	Pres & Chief Operating Officer	Oct 01 '26	Option Exercise	0.00	17,562	0	198,640	Oct 05 04:29 PM
Stone Warren	Pres & Chief Operating Officer	Aug 21 '26	Option Exercise	0.00	28,106	0	192,138	Aug 25 04:33 PM
Aunan Greg D	Chief Accounting Officer	Aug 04 '26	Sale	16.07	20,000	321,400	5,153	Aug 06 04:02 PM
GREG AUNAN	Officer	Aug 04 '26	Proposed Sale	16.07	20,000	321,480		Aug 04 04:20 PM
JEFFREY SHERMAN	Former Affliate	Jul 30 '26	Proposed Sale	15.64	236,876	3,704,556		Jul 30 04:05 PM
TETRAULT LYNN A.	Director	Jun 15 '26	Sale	11.10	5,307	58,908	86,115	Jun 17 04:07 PM
LYNN TETRAULT	Director	Jun 15 '26	Proposed Sale	11.15	5,307	59,173		Jun 15 04:36 PM
TETRAULT LYNN A.	Director	Jun 09 '26	Sale	11.29	5,307	59,916	91,422	Jun 11 04:10 PM
LYNN TETRAULT	Director	Jun 09 '26	Proposed Sale	10.95	5,307	58,112		Jun 09 04:22 PM
Kenny John P.	Director	Jun 01 '26	Option Exercise	0.00	5,893	0	5,893	Jun 03 07:48 PM
Williams Felicia	Director	Jun 01 '26	Option Exercise	0.00	23,077	0	30,237	Jun 03 07:47 PM
TETRAULT LYNN A.	Director	Jun 01 '26	Option Exercise	0.00	23,077	0	96,729	Jun 03 07:47 PM
Perez David Brian	Director	Jun 01 '26	Option Exercise	0.00	23,077	0	56,967	Jun 03 07:46 PM
Kelly Michael Aaron	Director	Jun 01 '26	Option Exercise	0.00	23,077	0	67,086	Jun 03 07:46 PM
KANOVSKY STEPHEN M	Director	Jun 01 '26	Option Exercise	0.00	23,077	0	75,421	Jun 03 07:46 PM
Gunn Neil	Director	Jun 01 '26	Option Exercise	0.00	23,077	0	51,177	Jun 03 07:45 PM
Green Marjorie C	Director	Jun 01 '26	Option Exercise	0.00	22,964	0	22,964	Jun 03 07:45 PM
Olivo Alicia C	EVP, GC & Business Development	May 11 '26	Option Exercise	0.00	3,944	0	96,126	May 13 04:19 PM
Stone Warren	Pres & Chief Operating Officer	May 11 '26	Option Exercise	0.00	5,830	0	167,815	May 13 04:18 PM
Aunan Greg D	Chief Accounting Officer	May 02 '26	Option Exercise	0.00	5,372	0	26,462	May 05 04:27 PM
Stone Warren	Pres & Chief Operating Officer	May 02 '26	Option Exercise	0.00	5,969	0	164,334	May 05 04:26 PM
Stone Warren	Pres & Chief Operating Officer	Apr 01 '26	Option Exercise	0.00	17,562	0	165,276	Apr 03 04:39 PM
Zook Anthony P.	Chief Executive Officer	Apr 01 '26	Option Exercise	0.00	140,498	0	178,564	Apr 03 04:38 PM
Stone Warren	Pres & Chief Operating Officer	Feb 23 '26	Option Exercise	0.00	8,443	0	151,037	Feb 24 04:15 PM
Stone Warren	Pres & Chief Operating Officer	Feb 21 '26	Option Exercise	0.00	28,105	0	149,736	Feb 24 04:15 PM
Sherman Jeffrey Scott	Chief Financial Officer	Feb 23 '26	Option Exercise	0.00	15,535	0	223,792	Feb 24 04:15 PM
Sherman Jeffrey Scott	Chief Financial Officer	Feb 21 '26	Option Exercise	0.00	42,158	0	218,986	Feb 24 04:15 PM
Olivo Alicia C	EVP, GC & Business Development	Feb 23 '26	Option Exercise	0.00	8,443	0	96,547	Feb 24 04:14 PM
Olivo Alicia C	EVP, GC & Business Development	Feb 21 '26	Option Exercise	0.00	21,079	0	96,399	Feb 24 04:14 PM
Aunan Greg D	Chief Accounting Officer	Feb 21 '26	Option Exercise	0.00	6,323	0	23,902	Feb 24 04:14 PM
Stone Warren	Pres & Chief Operating Officer	Jan 20 '26	Sale	12.50	22,128	276,682	121,631	Jan 21 09:01 PM
WARREN STONE	Officer	Jan 20 '26	Proposed Sale	12.79	22,128	283,017		Jan 20 04:30 PM
Stone Warren	Pres & Chief Operating Officer	Jan 13 '26	Option Exercise	0.00	59,382	0	158,886	Jan 15 04:22 PM
Olivo Alicia C	EVP, GC & Business Development	Jan 13 '26	Option Exercise	0.00	59,382	0	90,465	Jan 15 04:22 PM
Olivo Alicia C	EVP, GC & Business Development	Nov 25 '25	Option Exercise	10.05	8,977	90,219	51,999	Nov 28 04:18 PM
Olivo Alicia C	EVP, GC & Business Development	Nov 25 '25	Sale	12.00	20,916	250,992	31,083	Nov 28 04:18 PM
ALICIA OLIVO	Officer	Nov 25 '25	Proposed Sale	11.61	11,939	138,612		Nov 25 04:27 PM

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

CEO & DirectorMr. Anthony P. Zook

President & COOMr. Warren Stone

Chief Digital & Information OfficerMs. Elizabeth A. Floegel

Chief People & Culture OfficerMr. Gary Passman

Executive VP & CFOMr. Abhishek Jain

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NEO

Neogenomics Inc

Upgrade your Finviz experience